We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+17.47%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.02B
AUM Growth
+$399M
Cap. Flow
+$261M
Cap. Flow %
8.64%
Top 10 Hldgs %
52.67%
Holding
175
New
36
Increased
34
Reduced
22
Closed
43

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$50.4M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$40.2M
3
MMSI icon
Merit Medical Systems
MMSI
+$32.5M
4
ABMD
Abiomed Inc
ABMD
+$30.5M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$24.6M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.5M
2
NXTM
NxStage Medical Inc.
NXTM
+$34.9M
3
TSRO
TESARO, Inc.
TSRO
+$25.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$24.6M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Consumer Discretionary 0.06%
3 Technology 0.04%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZSAN
126
DELISTED
Zosano Pharma Corporation
ZSAN
$260K 0.01%
714
– –
GRCE
127
Grace Therapeutics
GRCE
$33.8M
$176K 0.01%
3,887
– –
JUNO
128
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$93K οΉ€0.01%
+300,000
New +$15M
PBYI icon
129
CALL
Puma Biotechnology
PBYI
$398M
$55K οΉ€0.01%
+100,000
New +$11.2M
CAPR icon
130
Capricor Therapeutics
CAPR
$380M
$6K οΉ€0.01%
+400
New +$8.66K
ALNY icon
131
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-100,000
Closed -$2.31M
ALNY icon
132
PUT
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-420,000
Closed -$45K
ARDX icon
133
Ardelyx
ARDX
$1.24B
– –
-1,352,391
Closed -$7.57M
ATRA icon
134
Atara Biotherapeutics
ATRA
$72.6M
– –
-1,404
Closed -$581K
DBVT
135
PUT
DBV Technologies
DBVT
$813M
– –
-55,000
Closed -$2.81M
EXAS
136
DELISTED
Exact Sciences
EXAS
– –
-135,444
Closed -$6.38M
KYNB
137
Kyntra Bio
KYNB
$27.4M
– –
-344
Closed -$462K
GILD icon
138
Gilead Sciences
GILD
$165B
– –
-40,000
Closed -$3.24M
HRTX icon
139
Heron Therapeutics
HRTX
$93.4M
– –
-330,000
Closed -$5.33M
INCY icon
140
CALL
Incyte
INCY
$25.4B
– –
-100,000
Closed -$35K
INCY icon
141
Incyte
INCY
$25.4B
– –
-5,619
Closed -$656K
IONS icon
142
CALL
Ionis Pharmaceuticals
IONS
$8.93B
– –
-60,000
Closed -$24K
MCRB icon
143
Seres Therapeutics
MCRB
$45M
– –
-6,750
Closed -$2.17M
MOH icon
144
CALL
Molina Healthcare
MOH
$10.4B
– –
-50,000
Closed -$345K
NCNA
145
NuCana
NCNA
$5.04M
– –
-40
Closed -$3.67M
OSUR icon
146
OraSure Technologies
OSUR
$273M
– –
-54,729
Closed -$1.23M
RGEN icon
147
Repligen
RGEN
$6.91B
– –
-87,400
Closed -$3.35M
SAGE
148
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-215,000
Closed -$178K
TDOC icon
149
Teladoc Health
TDOC
$1.66B
– –
-14,641
Closed -$485K
TLPH icon
150
Talphera
TLPH
$68M
– –
-62,230
Closed -$5.72M
3 4 5
6
7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Perceptive Advisors held 175 positions worth $3.02B, up 15% from $2.62B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors deployed $261M of net new capital in Q4 2017, opening 36 new positions and adding to 34 existing holdings. Its largest new stake was Zimmer Biomet: 206,000 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $57.5M trimmed.

  • Perceptive Advisors's largest Q4 2017 buy was Zimmer Biomet: 206,000 shares worth $24.1M.
  • Perceptive Advisors added most to Blueprint Medicines in Q4 2017, an estimated $50.4M increase.
  • Perceptive Advisors's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $57.5M.
  • Perceptive Advisors fully exited NxStage Medical Inc. in Q4 2017, selling an estimated $34.9M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $3.02B portfolio in Q4 2017.
  • Perceptive Advisors opened 36 new positions and closed 43 in Q4 2017.
  • Perceptive Advisors's portfolio value rose 15% quarter-over-quarter to $3.02B.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.